Comparing haemophilus influenzae type b conjugate vaccine schedules: A systematic review and meta-analysis of vaccine trials

Pediatric Infectious Disease Journal

Volumn 32, Issue 11, 2013, Pages 1245-1256

  Low, Nicola ^a   Redmond, Shelagh M ^a   Rutjes, Anne W S ^a,b   Martínez González, Nahara A ^a,c   Egger, Matthias ^a   Di Nisio, Marcello ^b,d   Scott, Pippa ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Haemophilus influenzae type b conjugate vaccine; meta analysis; systematic review; vaccine schedules

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G ANTIBODY; PHOSPHATE; POLYRIBOSYLRIBITOL PHOSPHATE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ARTICLE; ATTRIBUTABLE RISK; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS INFLUENZAE TYPE B INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INTENTION TO TREAT ANALYSIS; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; VACCINATION;

HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, CONJUGATE;

EID: 84886869355     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829f0a7e     Document Type: Article

References (53)

1. Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis. 2008;8:435-443.
2. Watt JP, Wolfson LJ, O'Brien KL, et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet. 2009;374:903-911.
3. World Health Organization. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec. 2006;81:445-452.
4. World Health Organization. WHO Vaccine Preventable Diseases Monitoring System: Immunization schedules by antigen. Available at: http://apps.who.int/ immunization-monitoring/globalsummary/schedules. Accessed July 29, 2013.
5. Fitzwater SP, Watt JP, Levine OS, et al. Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries. Hum Vaccin. 2010;6:810-818.
6. Swingler G, Fransman D, Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type B infections. Cochrane Database Syst Rev. 2007:CD001729.
7. Obonyo CO, Lau J. Efficacy of Haemophilus influenzae type b vaccination of children: a meta-analysis. Eur J Clin Microbiol Infect Dis. 2006;25:90-97.
8. Griffiths UK, Clark A, Gessner B, et al. Dose-specific efficacy of Haemophilus influenzae type b conjugate vaccines: a systematic review and meta-analysis of controlled clinical trials. Epidemiol Infect. 2012;140:1343-1355.
9. Theodoratou E, Johnson S, Jhass A, et al. The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality. Int J Epidemiol. 2010;39(suppl 1):i172-i185.
10. Goldblatt D, Assari T. Immunological basis for immunization series. Module 9: Haemophilus influenzae type b. 2007. Available at: http://whqlibdoc. who.int/publications/2007/9789241596138-eng.pdf. Accessed January 24, 2013.
11. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001;323:42-46.
12. Nüesch E, Trelle S, Reichenbach S, et al. The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. BMJ. 2009;339:b3244.
13. Nüesch E, Reichenbach S, Trelle S, et al. The importance of allocation concealment and patient blinding in osteoarthritis trials: a meta-epidemiologic study. Arthritis Rheum. 2009;61:1633-1641.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
15. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
16. Hoppenbrouwers K, Kanra G, Roelants M, et al. Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Vaccine. 1999;17:875-886.
17. Scheifele DW, Guasparini R, Lavigne P. A comparative study of PENTA vaccine booster doses given at 12, 15, or 18 months of age. Vaccine. 1999;17:543-550.
18. Scheifele DW, Halperin SA, Rubin E, et al. Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and haemophilus influenzae type B conjugate) when administered as a fourth dose at 15 to 18 months of age. Hum Vaccin. 2005;1:180-186.
19. Scheifele DW, Halperin SA, Ochnio JJ, et al. Immunologic considerations for the timing of the booster dose of 7-valent pneumococcal conjugate vaccine in young children. Pediatr Infect Dis J. 2007;26:387-392.
20. Lagos R, Valenzuela MT, Levine OS, et al. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet. 1998;351:1472-1476.
21. Lagos R, Kotloff K, Hoffenbach A, et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and sixmonth- old Chilean infants. Pediatr Infect Dis J. 1998;17:294-304.
22. Li RC, Li FX, Li YP, et al. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV// PRP approximately T vaccine compared to separate vaccines (DTaP, PRP approximately T and IPV) following primary vaccination of healthy infants in the People's Republic of China. Vaccine. 2011;29:9337-9344.
23. GlaxoSmithKline. Immunogenicity and safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+Hib™) in infants. Results summary for study ID 112584. Available at: http://www.gsk-clinicalstudyregister. com. Accessed January 24, 2013.
24. Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. Vaccine. 2011;29:4264-4273.
25. European Medicines Agency. Hexavac, scientific discussion. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000298/WC500074582.pdf. Accessed January 24, 2013.
26. Campbell H, Byass P, Ahonkhai VI, et al. Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants. Pediatrics. 1990;86:102-107.
27. Mulholland EK, Byass P, Campbell H, et al. The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants. Ann Trop Paediatr. 1994;14:183-188.
28. Asturias EJ, Mayorga C, Caffaro C, et al. Differences in the immune response to hepatitis B and Haemophilus influenzae type b vaccines in Guatemalan infants by ethnic group and nutritional status. Vaccine. 2009;27:3650-3654.
29. Labadie J, Sundermann L, Rumke H. The DPT-IPV Hib vaccine study group. Multi-center study on the simultaneous administration of DPT-IPV and Hib PRP-T vaccines. Rijksinstituut voor Volksgezondheid en Milieu RIVM. 1996. Available at: http://www.rivm.nl/bibliotheek/rapporten/124001003. html. Accessed January 24, 2013.
30. Campagne G, Garba A, Schuchat A, et al. Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger. Am J Trop Med Hyg. 1998;59:837-842.
31. Carlsson RM, Claesson BA, Selstam U, et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine- Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J. 1998;17:1026-1033.
32. Anderson EL, Decker MD, Englund JA, et al. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA. 1995;273:849-853.
33. Lieberman JM, Greenberg DP, Wong VK, et al. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines. J Pediatr. 1995;126: 198-205.
34. Lenoir AA, Granoff PD, Granoff DM. Immunogenicity of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in 2- to 6-month-old infants. Pediatrics. 1987;80:283-287.
35. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.
36. Sibbald B, Roland M. Understanding controlled trials. Why are randomised controlled trials important? BMJ. 1998;316:201.
37. O'Loughlin RE, Edmond K, Mangtani P, et al. Methodology and measurement of the effectiveness of Haemophilus influenzae type b vaccine: systematic review. Vaccine. 2010;28:6128-6136.
38. Jackson C, Mann A, Mangtani P, et al. Effectiveness of Haemophilus influenzae type b (Hib) vaccines administered according to different schedules: systematic review and meta-analysis of observational data. Pediatr Infect Dis J. 2013;32:1261-1269.
39. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.
40. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med. 1991;324:1767-1772.
41. Lagos R, Horwitz I, Toro J, et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J. 1996;15:216-222.
42. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet. 1997;349:1191-1197.
43. Gessner BD, Sutanto A, Linehan M, et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet. 2005;365:43-52.
44. Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J. 1991;10:97-104.
45. Higgins JP, Whitehead A. Borrowing strength from external trials in a metaanalysis. Stat Med. 1996;15:2733-2749.
46. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:3105-3124.
47. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17:154-159.
48. Southern J, McVernon J, Gelb D, et al. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol. 2007;14:1328-1333.
49. Ladhani S, Slack MP, Heys M, et al. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child. 2008;93:665-669.
50. Slack MP, Azzopardi HJ, Hargreaves RM, et al. Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines. Pediatr Infect Dis J. 1998;17(suppl 9):S204-S207.
51. McVernon J, Andrews N, Slack MP, et al. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet. 2003;361:1521-1523.
52. McVernon J, Andrews N, Slack M, et al. Host and environmental factors associated with Hib in England, 1998-2002. Arch Dis Child. 2008;93:670-675.
53. Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381:214-222.